Passage Bio Inc (PASG) concluded trading on Thursday at a closing price of $0.83, with 6.66 million shares of worth about $5.53 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.92% during that period and on Thursday the price saw a gain of about 46.36%. Currently the company’s common shares owned by public are about 61.77M shares, out of which, 51.56M shares are available for trading.
Stock saw a price change of 27.42% in past 5 days and over the past one month there was a price change of -17.82%. Year-to-date (YTD), PASG shares are showing a performance of 46.36% which decreased to -7.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.45 but also hit the highest price of $1.79 during that period. The average intraday trading volume for Passage Bio Inc shares is 620.43K. The stock is currently trading 17.54% above its 20-day simple moving average (SMA20), while that difference is up 24.12% for SMA50 and it goes to -8.54% lower than SMA200.
Passage Bio Inc (NASDAQ: PASG) currently have 61.77M outstanding shares and institutions hold larger chunk of about 44.02% of that.
The stock has a current market capitalization of $51.27M and its 3Y-monthly beta is at 1.54. It has posted earnings per share of -$1.17 in the same period. It has Quick Ratio of 5.15 while making debt-to-equity ratio of 0.36. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PASG, volatility over the week remained 22.22% while standing at 14.33% over the month.
Stock’s fiscal year EPS is expected to rise by 47.04% while it is estimated to increase by 33.20% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wedbush on November 29, 2024 offering an Outperform rating for the stock and assigned a target price range of between $3 and $4 to it. Coverage by Rodman & Renshaw stated Passage Bio Inc (PASG) stock as a Buy in their note to investors on September 03, 2024, suggesting a price target of $7 for the stock. On March 08, 2022, JP Morgan Downgrade their recommendations, while on January 19, 2022, Goldman Downgrade their ratings for the stock with a price target of $6. Stock get an Outperform rating from Raymond James on July 01, 2021.
